Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $16.60.
VIGL has been the topic of several research analyst reports. Guggenheim decreased their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a report on Friday, November 8th. William Blair started coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating for the company. Wedbush increased their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th.
View Our Latest Stock Report on VIGL
Vigil Neuroscience Stock Up 0.9 %
Hedge Funds Weigh In On Vigil Neuroscience
Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after purchasing an additional 66,712 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Vigil Neuroscience by 7.7% in the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after buying an additional 115,000 shares during the period. Verition Fund Management LLC bought a new stake in shares of Vigil Neuroscience in the 3rd quarter valued at about $442,000. Walleye Capital LLC boosted its holdings in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after acquiring an additional 92,217 shares during the period. Finally, abrdn plc bought a new position in Vigil Neuroscience during the 3rd quarter worth approximately $799,000. Institutional investors own 83.64% of the company’s stock.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Stories
- Five stocks we like better than Vigil Neuroscience
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Guidewire Software Provides Long-Awaited Buying Opportunity
- Conference Calls and Individual Investors
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- How to buy stock: A step-by-step guide for beginners
- Fast-Growing Companies That Are Still Undervalued
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.